MX369443B - Variantes del lantibiotico mu1140 y otros lantibioticos con propiedades farmacologicas y caracteristicas estructurales mejoradas. - Google Patents

Variantes del lantibiotico mu1140 y otros lantibioticos con propiedades farmacologicas y caracteristicas estructurales mejoradas.

Info

Publication number
MX369443B
MX369443B MX2014010151A MX2014010151A MX369443B MX 369443 B MX369443 B MX 369443B MX 2014010151 A MX2014010151 A MX 2014010151A MX 2014010151 A MX2014010151 A MX 2014010151A MX 369443 B MX369443 B MX 369443B
Authority
MX
Mexico
Prior art keywords
lantibiotics
amino acid
variants
lantibiotic
structural features
Prior art date
Application number
MX2014010151A
Other languages
English (en)
Spanish (es)
Other versions
MX2014010151A (es
Inventor
D Hillman Jeffrey
Leif Smith James
R Wilson-Stanford Shawanda
Original Assignee
Oragenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oragenics Inc filed Critical Oragenics Inc
Publication of MX2014010151A publication Critical patent/MX2014010151A/es
Publication of MX369443B publication Critical patent/MX369443B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20Bacteria; Substances produced thereby or obtained therefrom
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/34Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/12Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G4/123Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01001Alcohol dehydrogenase (1.1.1.1)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
MX2014010151A 2012-02-27 2013-02-22 Variantes del lantibiotico mu1140 y otros lantibioticos con propiedades farmacologicas y caracteristicas estructurales mejoradas. MX369443B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603693P 2012-02-27 2012-02-27
US201261603661P 2012-02-27 2012-02-27
PCT/US2013/027336 WO2013130349A1 (en) 2012-02-27 2013-02-22 Variants of the lantibiotic mu1140 and other lantibiotics with improved pharmacological properties and structural features

Publications (2)

Publication Number Publication Date
MX2014010151A MX2014010151A (es) 2015-01-14
MX369443B true MX369443B (es) 2019-11-08

Family

ID=49083172

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014010151A MX369443B (es) 2012-02-27 2013-02-22 Variantes del lantibiotico mu1140 y otros lantibioticos con propiedades farmacologicas y caracteristicas estructurales mejoradas.
MX2014010143A MX358060B (es) 2012-02-27 2013-02-22 Cepa de streptococcus mutans para usarse en terapia de reemplazo para caries dentales.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014010143A MX358060B (es) 2012-02-27 2013-02-22 Cepa de streptococcus mutans para usarse en terapia de reemplazo para caries dentales.

Country Status (10)

Country Link
US (2) US9963488B2 (enExample)
EP (3) EP2833902A4 (enExample)
JP (2) JP6297506B2 (enExample)
CN (2) CN104321338B (enExample)
AU (2) AU2013226402B2 (enExample)
BR (2) BR112014020659A2 (enExample)
CA (2) CA2865405C (enExample)
HK (2) HK1205519A1 (enExample)
MX (2) MX369443B (enExample)
WO (2) WO2013130349A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201810952PA (en) * 2016-07-15 2019-01-30 Intrexon Corp Lantibiotic variants and uses thereof
US10577399B2 (en) 2016-10-28 2020-03-03 The Texas A&M University System Modified lantibiotics and methods of making and using the modified lantibiotics
WO2020090045A1 (ja) * 2018-10-31 2020-05-07 株式会社村田製作所 抗グラム陰性菌化合物
EP3935067A4 (en) * 2019-03-08 2022-12-07 Fraunhofer USA, Inc. NEW ANTIMICROBIAL LANTIBIOTIC PEPTIDE AND ASSOCIATED USES
CN118490568B (zh) * 2024-07-16 2024-10-18 南昌怀特科技有限公司 一种用于牙齿美白的抑菌凝胶及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US5516682A (en) 1988-07-05 1996-05-14 University Of Maryland Subtilin variant of enhanced stability and activity
GB9423404D0 (en) * 1994-11-19 1995-01-11 Biotech & Biolog Scien Res Production of nisin
US20060198793A1 (en) * 1997-06-10 2006-09-07 University Of Florida Research Foundation Antimicrobial polypeptide, nucleic acid, and methods of use
US5932469A (en) * 1997-06-10 1999-08-03 University Of Florida Antimicrobial polypeptide, nucleic acid, and methods of use
US6964760B2 (en) 1997-06-10 2005-11-15 University Of Florida Research Foundation Antimicrobial polypeptide, nucleic acid, and methods of use
US6251478B1 (en) 1999-12-22 2001-06-26 Balchem Corporation Sensitive substance encapsulation
EP1483366B1 (en) * 2002-02-22 2010-04-14 Blis Technologies Limited Antimicrobial composition
ATE512158T1 (de) 2005-08-12 2011-06-15 Oragenics Inc Differenziell geschützte, orthogonale lanthionintechnologie
US20090215985A1 (en) * 2005-08-12 2009-08-27 Oragenics, Inc. Differentially protected orthogonal lanthionine technology
US7576054B2 (en) * 2005-10-11 2009-08-18 Biosynexus Incorporated Compositions and methods for treating bacteria
US20110150917A1 (en) * 2007-06-12 2011-06-23 The University Of British Columbia Small Cationic Antimicrobial Peptides
DK2176284T3 (da) * 2007-07-20 2013-10-14 Univ Minnesota Lantibiotika og anvendelser deraf
IE20080365A1 (en) * 2008-05-09 2010-03-16 Univ College Cork Nat Univ Ie Nisin derivatives and the use thereof

Also Published As

Publication number Publication date
US9963488B2 (en) 2018-05-08
BR112014020659A2 (pt) 2017-06-27
AU2013226402B2 (en) 2017-05-18
WO2013130349A8 (en) 2014-01-09
HK1205519A1 (en) 2015-12-18
EP2833902A1 (en) 2015-02-11
MX2014010143A (es) 2015-04-08
US20150044146A1 (en) 2015-02-12
WO2013130349A1 (en) 2013-09-06
CA2865395A1 (en) 2013-09-06
JP6297506B2 (ja) 2018-03-20
JP6309902B2 (ja) 2018-04-11
CN104302307B (zh) 2018-10-26
JP2015509715A (ja) 2015-04-02
CN104321338B (zh) 2018-10-19
HK1205458A1 (en) 2015-12-18
JP2015509945A (ja) 2015-04-02
WO2013130351A1 (en) 2013-09-06
BR112014020656A2 (pt) 2017-06-27
MX2014010151A (es) 2015-01-14
EP2833902A4 (en) 2016-04-06
CA2865405A1 (en) 2013-09-06
CN104302307A (zh) 2015-01-21
EP3219325A1 (en) 2017-09-20
CN104321338A (zh) 2015-01-28
EP2820036A4 (en) 2016-01-20
AU2013226404A1 (en) 2014-08-21
US20150125503A1 (en) 2015-05-07
EP2820036B1 (en) 2018-06-06
AU2013226402A1 (en) 2014-08-21
EP2820036A1 (en) 2015-01-07
US9260488B2 (en) 2016-02-16
EP3219325B1 (en) 2019-11-06
AU2013226404B2 (en) 2017-11-30
CA2865405C (en) 2021-11-16
MX358060B (es) 2018-08-03

Similar Documents

Publication Publication Date Title
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
MX369443B (es) Variantes del lantibiotico mu1140 y otros lantibioticos con propiedades farmacologicas y caracteristicas estructurales mejoradas.
GB201016733D0 (en) Compounds and their use
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
EP4230644A3 (en) Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
WO2015153761A3 (en) Macrocyclic peptidomimetics for alpha-helix mimicry
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
WO2015013330A3 (en) Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
PH12013502363A1 (en) Avirulent modified salmonella gallinarum strains and pharmaceutical composition using the same
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
GB201211617D0 (en) Production of cyclic peptides
NZ629130A (en) Tfpi inhibitors and methods of use
GB201110815D0 (en) Incorporation of subtituted lysines into polypeptides
MX2015003343A (es) Tratamiento combinado con el farmaco de interferencia de netrina-1 y el farmaco quimioterapeutico.
IN2013MU01985A (enExample)
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
CL2015001258A1 (es) Uso combinado de volasertib en asociacion con gcsf, fludarabina, citarabina, y uso combinado de volasertib en asociacion con gcsf, fludarabina, citarabina y citrato de daunorrubicina, para el tratamiento de la leucemia mieloide aguda (aml); composicion faramceutica.
HK1212978A1 (zh) 芥子酸的新型衍生物
MX2016003533A (es) Tripeptidos antiinflamatorios.
EP3086779A4 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
WO2015069979A3 (en) Sulfated and unsulfated flavonoid oligomers as cancer therapeutics
EP3064489A4 (en) Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof
IN2015DN02109A (enExample)

Legal Events

Date Code Title Description
FG Grant or registration